How to facilitate early diagnosis of CNS involvement in malignant lymphoma

References

• Haioun C, Besson C, Lepage E, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin’s lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d’Etudes des Lymphomes de l’Adulte. Ann Oncol. 2000;11(6):685–690.
   PubMed Web of Science ®Google Scholar
• Villa D, Connors JM, Shenkier TN, et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 2010;21(5):1046–1052.
   PubMed Web of Science ®Google Scholar
• Boehme V, Schmitz N, Zeynalova S, et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009;113(17):3896–3902.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Zeynalova S, Glass B, et al. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the mabthera international trial and trials of the German high-grade non-hodgkin lymphoma study group. Ann Oncol. 2012 May;23(5):1267–1273.
   PubMed Web of Science ®Google Scholar
• Bernstein SH, Unger JM, Leblanc M, et al. Natural history of CNS relapse in patients with aggressive non-Hodgkin’s lymphoma: a 20-year follow-up analysis of SWOG 8516 – the Southwest oncology group. J Clin Oncol. 2009;27(1):114–119.
   PubMed Web of Science ®Google Scholar
• Hegde U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood. 2005;105(2):496–502.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Zeynalova S, Nickelsen M, et al. CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-Cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34(26):3150–3156.
   Google Scholar
• Korfel A, Elter T, Thiel E, et al. Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica. 2013;98(3):364–370.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Donadoni G, Cabras MG, et al. High doses of antimetabolites followed by high-dose sequential chemoimmunotherapy and autologous stem-cell transplantation in patients with systemic b-cell lymphoma and secondary CNS involvement: final results of a multicenter phase II trial. J Clin Oncol. 2015;33(33):3903–3910.
   PubMed Web of Science ®Google Scholar
• Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer. 1982;49:759–772.
   PubMed Web of Science ®Google Scholar
• Van Horn A, Chamberlain M. Neoplastic meningitis. J Supp Oncol. 2012;10(2):45-53.
   PubMedGoogle Scholar
• Chamberlain MC, Sandy AD, Press GA. Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology. 1990;40(3 Pt 1):435–438.
   PubMed Web of Science ®Google Scholar
• Lombardi G, Zustovich F, Farina P, et al. Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches. Oncologist. 2011;16(8):1175–1188.
   PubMed Web of Science ®Google Scholar
• Mahendru G, Chong V. Meninges in cancer imaging. Cancer Imaging. 2009;9:Spec No A:S14-S21.
   PubMedGoogle Scholar
• Khil EK, Lee AL, Chang KH, et al. Symmetrical curvilinear cytotoxic edema along the surface of the brain stem: a probable new magnetic resonance imaging finding of leptomeningeal carcinomatosis. Medicine. 2015;94(21):e1053.
   PubMed Web of Science ®Google Scholar
• Zeiser R, Burger JA, Bley TA, et al. Clinical follow-up indicates differential accuracy of magnetic resonance imaging and immunocytology of the cerebral spinal fluid for the diagnosis of neoplastic meningitis - a single centre experience. Brit J Haematol. 2004;124(6):762–768.
   PubMed Web of Science ®Google Scholar
• Straathof CS, De Bruin HG, Dippel DW, et al. The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis. J Neurol. 1999;246(9):810–814.
   PubMed Web of Science ®Google Scholar
• Pauls S, Fischer AC, Brambs HJ, et al. Use of magnetic resonance imaging to detect neoplastic meningitis: limited use in leukemia and lymphoma but convincing results in solid tumors. Eur J Radiol. 2012;81(5):974–978.
   PubMed Web of Science ®Google Scholar
• Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol. 1995;38(1):51–57.
   PubMed Web of Science ®Google Scholar
• Clarke JL, Perez HR, Jacks LM, et al. Leptomeningeal metastases in the MRI era. Neurology. 2010;74(18):1449–1454.
   PubMed Web of Science ®Google Scholar
• Korfel A, Weller M, Martus P, et al. Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial. Ann Oncol. 2012;23(9):2374–2380.
   PubMed Web of Science ®Google Scholar
• Prommel P, Pilgram-Pastor S, Sitter H, et al. Neoplastic meningitis: how MRI and CSF cytology are influenced by CSF cell count and tumor type. Scientific World J. 2013;2013:1–5.
   Web of Science ®Google Scholar
• Tsuchiya K, Katase S, Yoshino A, et al. FLAIR MR imaging for diagnosing intracranial meningeal carcinomatosis. Am J Rad. 2001;176(6):1585–1588.
   Web of Science ®Google Scholar
• Haldorsen IS, Espeland A, Larsson EM. Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. Am J Neurol. 2011;32(6):984–992.
   Google Scholar
• Siegal T, Goldschmidt N. CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom? Blood Rev. 2012;26(3):97–106.
   PubMed Web of Science ®Google Scholar
• Kuker W, Nagele T, Korfel A, et al. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol. 2005;72(2):169–177.
   PubMed Web of Science ®Google Scholar
• Calli C, Kitis O, Yunten N, et al. Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors. Eur J Radiol. 2006;58(3):394–403.
   PubMed Web of Science ®Google Scholar
• Kickingereder P, Wiestler B, Sahm F, et al. Primary central nervous system lymphoma and atypical glioblastoma: multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging. Radiology. 2014;272(3):843–850.
   PubMed Web of Science ®Google Scholar
• Komori T, Delbeke D. Leptomeningeal carcinomatosis and intramedullary spinal cord metastases from lung cancer: detection with FDG positron emission tomography. Clin Nucl Med. 2001;26(11):905–907.
   PubMed Web of Science ®Google Scholar
• Chawla M, Reddy R, Kumar R, et al. PET-CT in detection of meningeal metastasis in neuroblastoma. Ped Surg Int. 2009;25(2):211–215.
   PubMed Web of Science ®Google Scholar
• Tonomura Y, Kataoka H, Terashima M, et al. Detection of neoplastic meningitis in a patient with gastric cancer by thallium-201 SPECT. J Radiol Case Rep. 2009;3(4):9–13.
   PubMedGoogle Scholar
• Watanabe N, Shimizu M, Noguchi K, et al. Detecting meningeal carcinomatosis from breast cancer with thallium-201 SPECT. Ann Nucl Medi. 2000;14(5):379–381.
   PubMed Web of Science ®Google Scholar
• Akkas BE, Vural GU. The incidence of secondary central nervous system involvement in patients with non-Hodgkin’s lymphoma as detected by 18F-FDG PET/CT. Nucl Med Commun. 2013;34(1):50–56.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Kormanik PA. Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology. 1996;46(6):1674–1677.
   PubMed Web of Science ®Google Scholar
• Mason WP, Yeh SD, DeAngelis LM. 111Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology. 1998;50(2):438–444.
   PubMed Web of Science ®Google Scholar
• Chamberlain M, Junck L, Brandsma D, et al. Leptomeningeal metastases: a RANO proposal for response criteria. J Clin Oncol. 2014;32(25):2765–2772.
   PubMed Web of Science ®Google Scholar
• Kaplan JG, DeSouza TG, Farkash A, et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol. 1990 Dec;9(3):225–229.
   PubMed Web of Science ®Google Scholar
• Balmaceda C, Gaynor JJ, Sun M, et al. Leptomeningeal tumor in primary central nervous system lymphoma: recognition, significance, and implications. Ann Neurol. 1995;38(2):202–209.
   PubMed Web of Science ®Google Scholar
• Glass JP, Melamed M, Chernik NL, et.al. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology. 2015;94(21):1369–1375.
   Google Scholar
• Glantz MJ, Cole BF, Glantz LK, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer. 1998;82:733–739.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Kormanik PA, Glantz MJ. A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases. Neuro Oncol. 2001;3(1):42.
   PubMed Web of Science ®Google Scholar
• Alvarez R, Dupuis J, Plonquet A, et al. Clinical relevance of flow cytometric immunophenotyping of the cerebrospinal fluid in patients with diffuse large B-cell lymphoma. Ann Oncol. 2012;23(5):1274–1279.
   PubMed Web of Science ®Google Scholar
• Subira D, Castanon S, Aceituno E, et al. Flow cytometric analysis of cerebrospinal fluid samples and its usefulness in routine clinical practice. Am J Clin Pathol. 2009;27(1):114–119.
   Google Scholar
• Quijano S, Lopez A, Manuel Sancho J, et al. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin’s lymphoma: improved sensitivity of flow cytometry. J Clin Oncol. 2009;27(9):1462–1469.
   PubMed Web of Science ®Google Scholar
• de Graaf MT, Van Den Broek PD, Kraan J, et al. Addition of serum-containing medium to cerebrospinal fluid prevents cellular loss over time. J Neurol. 2011;258(8):1507–1512.
   PubMed Web of Science ®Google Scholar
• de Jongste AH, Kraan J, van den Broek PD, et al. Use of transfix cerebrospinal fluid storage tubes prevents cellular loss and enhances flow cytometric detection of malignant hematological cells after 18 hours of storage. Cytometry B Clin Cytom. 2010;74(18):1449–1454.
   Google Scholar
• Kraan J, Gratama JW, Haioun C, et al. Flow cytometric immunophenotyping of cerebrospinal fluid. Current Protocols in Cytometry. 2008;Hoboken, (NJ):Wiley.
   Google Scholar
• Di Noto R, Scalia G, Abate G, et al. Critical role of multidimensional flow cytometry in detecting occult leptomeningeal disease in newly diagnosed aggressive B-cell lymphomas. Leuk. 2008;32(8):1196–1199.
   Web of Science ®Google Scholar
• Benevolo G, Stacchini A, Spina M, et al. Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. Blood. 2012;120(16):3222–3228.
   PubMed Web of Science ®Google Scholar
• Van Dongen JJ, Orfao A. EuroFlow consortium euroflow: resetting leukemia and lymphoma immunophenotyping. Basis Companion Diagnostics Personalized Medicine. Leukemia. 2012;26(9):1899–1907.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Bromberg JE, Stetler-Stevenson M, et al. Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica. 2014;99(7):1228–1235.
   PubMed Web of Science ®Google Scholar
• Cheng TM, O’Neill BP, Scheithauer BW, et al. Chronic meningitis: the role of meningeal or cortical biopsy. Neurosurgery. 1994;34(4):590–596.
   PubMed Web of Science ®Google Scholar
• Muniz C, Martin-Martin L, Lopez A, et al. Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome. Blood. 2014;123(12):1864–1869.
   PubMed Web of Science ®Google Scholar
• Roy S, Josephson SA, Fridlyand J, et al. Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol. 2008;26(1):96–105.
   PubMed Web of Science ®Google Scholar
• Baraniskin A, Kuhnhenn J, Schlegel U, et al. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood. 2011;117(11):3140–3146.
   PubMed Web of Science ®Google Scholar
• Kersten MJ, Evers LM, Dellemijn PL, et al. Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies. Blood. 1996;87(5):1985–1989.
   PubMed Web of Science ®Google Scholar
• Fischer L, Korfel A, Pfeiffer S, et al. CXCL13 and CXCL12 in central nervous system lymphoma patients. Clin Cancer Res. 2009;15(19):5968–5973.
   PubMed Web of Science ®Google Scholar
• Viaccoz A, Ducray F, Tholance Y, et al. CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma. Neurooncol. 2015;17(11):1497–1503.
   Google Scholar
• Murase S, Saio M, Takenaka K, et al. Increased levels of CSF soluble CD27 in patients with primary central nervous system lymphoma. Cancer Lett. 1998;132(1–2):181–186.
   PubMed Web of Science ®Google Scholar
• Murase S, Saio M, Andoh H, et al. Diagnostic utility of CSF soluble CD27 for primary central nervous system lymphoma in immunocompetent patients. Neurol Res. 2000;22(5):434–442.
   PubMed Web of Science ®Google Scholar
• Cassoux N, Giron A, Bodaghi B, et al. IL-10 measurement in aqueous humor for screening patients with suspicion of primary intraocular lymphoma. Invest Ophthalmol Vis Sci. 2007;48(7):3253–3259.
   PubMed Web of Science ®Google Scholar
• Buggage RR, Whitcup SM, Nussenblatt RB, et al. Using interleukin 10 to interleukin 6 ratio to distinguish primary intraocular lymphoma and uveitis. Invest Ophthalmol Vis Sci. 1999;40(10):2462–2463.
   PubMed Web of Science ®Google Scholar
• Whitcup SM, Stark-Vancs V, Wittes RE, et al. Association of interleukin 10 in the vitreous and cerebrospinal fluid and primary central nervous system lymphoma. Arch Ophthalmol. 1997;115(9):1157–1160.
   PubMedGoogle Scholar
• Sasayama T, Nakamizo S, Nishihara M, et al. Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL). Neuro Oncol. 2012;14(3):368–380.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Wong VS, Kadoch C, et al. CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood. 2013;121(23):4740–4748.
   PubMed Web of Science ®Google Scholar
• Nguyen-Them L, Costopoulos M, Tanguy ML, et al. The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients. French LOC network for CNS Lymphoma. Eur J Cancer. 2016;61:69–76.
   PubMed Web of Science ®Google Scholar
• Gleissner B, Siehl J, Korfel A, et al. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology. 2002;58(3):390–396.
   PubMed Web of Science ®Google Scholar
• Fischer L, Martus P, Weller M, et al. Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. Neurology. 2008;71(14):1102–1108.
   PubMed Web of Science ®Google Scholar
• Rock JP, Cher L, Hochberg FH. Central nervous system lymphomas in AIDS and non-AIDS patients. In: Yomans JR, et al. Editors. Neurological surgery. 4th ed. Philadelphia: WB Saunders; 1995.
   Google Scholar
• Hochberg FH, Miller DC. Primary central nervous system lymphoma. J Neurosurg. 1988;68(3):449–455.
   PubMed Web of Science ®Google Scholar
• Mneimneh WS, Ashraf MA, Li L, et al. Primary dural lymphoma: a novel concept of heterogeneous disease. Pathol Int. 2013;63(1):68–72.
   PubMed Web of Science ®Google Scholar
• Sugita Y, Muta H, Ohshima K, et al. Primary central nervous system lymphomas and related diseases: pathological characteristics and discussion of the differential diagnosis. Neuropathology. 2016;36(4):313–324.
   Web of Science ®Google Scholar
• Da Rocha AJ, Sobreira Guedes BV, Da Silveira Da Rocha TM, et al. Modern techniques of magnetic resonance in the evaluation of primary central nervous system lymphoma: contributions to the diagnosis and differential diagnosis. Rev Bras Hematol Hemoter. 2016;38(1):44–54.
   PubMedGoogle Scholar
• Deckert M, Engert A, Brück W, et al. Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia. 2011;25(12):1797–1807.
   PubMed Web of Science ®Google Scholar
• Graus F, Ariño H, Dalmau J. Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. Blood. 2014;123(21):3230–3238.
   PubMed Web of Science ®Google Scholar
• Ahmed RM, Halmagyi GM. Malignant meningitis presenting as pseudotumor cerebri. J Sci. 2013;329(1–2):62–65.
   Google Scholar
• Tha KK, Terae S, Kudo K, et al. Differential diagnosis of hyperintense cerebrospinal fluid on fluid-attenuated inversion recovery images of the brain. part II: non-pathological conditions. Brit J Radiol. 2009;82(979):610–614.
   PubMed Web of Science ®Google Scholar
• Tha KK, Terae S, Kudo K, et al. Differential diagnosis of hyperintense cerebrospinal fluid on fluid-attenuated inversion recovery images of the brain. Part I: pathological conditions. Brit J Radiol. 2009;82(977):426–434.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034–5043.
   PubMed Web of Science ®Google Scholar
• Chamberlain M, Soffietti R, Raizer J, et al. Leptomeningeal metastasis: a response assessment in neuro-oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro Oncol. 2014;16(9):1176–1185.
   PubMed Web of Science ®Google Scholar